PRECURSOR AND RADIOTRACER FOR NEUROENDOCRINE THERANOSTICS
A precursor designated as DAZTA5-PPA2 for PET/CT diagnosis and nuclear therapy|of SSR active lesions with radioisotopes 68Ga and 177Lu provides improved|affinity, specificity and imaging of small metastases.
1 . Precursor DAZTA 5 -PPA2 for neuroendocrine theranostics having structure
with
and
or a salt thereof.
2 . Radiotracer 68 Ga-DAZTA 5 -PPA2 according to claim 1 consisting of precursor DAZTA 5 -PPA2 with
and therewith complexed radioisotope 68 Ga.
3 . Radiotracer 177 Lu-DAZTA 5 -PPA2 according to claim 1 consisting of precursor DAZTA 5 -PPA2 with
and therewith complexed radioisotope 177 Lu.
4 . Radiopharmaceutical kit according to claim 1 comprising precursor DAZTA 5 -PPA2 with
or a salt thereof.
5 . Radiopharmaceutical kit according to claim 1 comprising precursor DAZTA 5 -PPA2 with
or a salt thereof.
6 . Radiopharmaceutical kit according to claim 4 comprising a solvent selected from water, 0.45% aqueous NaCl solution, 0.9% aqueous NaCl solution, Ringer solution (Ringer lactate), 5% aqueous dextrose solution and aqueous alcohol solution.
7 . Radiopharmaceutical kit according to claim 1 comprising
a first vial containing precursor DAZTA 5 -PPA2 with
or a salt thereof, and
a second vial containing precursor DAZTA 5 -PPA2 with
or a salt thereof.
8 . Radiopharmaceutical kit according to claim 7 comprising one or two solvents selected independently of one another from water, 0.45% aqueous NaCl solution, 0.9% aqueous NaCl solution, Ringer solution (Ringer lactate), 5% aqueous dextrose solution and aqueous alcohol solution.
9 . Use of the precursor of claim 1 for PET imaging, SPECT imaging or endoradiotherapy of somatostatin expressing tissue.
10 . Use of the radiotracer of claim 2 for PET imaging, SPECT imaging or endoradiotherapy of somatostatin expressing tissue.
11 . Use of the radiopharmaceutical kit of claim 6 for PET imaging, SPECT imaging or endoradiotherapy of somatostatin expressing tissue.